Enterprise Value
2.611M
Cash
35.98M
Avg Qtr Burn
-4.738M
Short % of Float
7.10%
Insider Ownership
3.43%
Institutional Own.
33.17%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roluperidone (5-HT2A antagonist) Details Central nervous system illness, Mental health, Schizophrenia | PDUFA Approval decision | |
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders | Failed Discontinued |